ABCB5 and recessive dystrophic epidermolysis bullosa: The results of preclinical and clinical studies allow one to conclude that the specific subpopulation of immunomodulating ABCB5+ MSCs isolated from the dermis of healthy donors is quite promising to treat RDEB.